Square Enix finally reveals its first NFT project – SYMBIOGENESIS
It's storytelling, collecting and of course, gameplay, all in one
Multimedia giant Square Enix finally unveils their much awaited NFT project. The brand new IP will focus on the gamification of NFT art collection as well as interactive storytelling.
The new NFT project is name SYMBIOGENESIS and is Square Enix’s “first digital collectible art project designed from the ground up for Web3 fans“. The announcement was made at Web3 Conclave, an event held within the India Game Developers Conference or IDGC.
According to its description, SYMBIOGENESIS is “set in a self-contained world where a wide cast of characters symbiosis, all of which can be collected as digital art“. The game’s story takes place in an alternate world where players uncover a mystery all while collecting NFTs. Square Enix plans for NFTs first came to light in the New Year’s Letter by company president Yosuke Matsuda. Since then, the company has been getting involved in multiple NFT properties. One of them includes bringing the Dungeon Siege franchise to The Sandbox. Square Enix is now also partners with Animoca Brands, and as well as Oasys for its web3 push. Aside from Square Enix, other known major development brands like SEGA, and Ubisoft are also part of the Oasys blockchain.
Square Enix is mainly known for creating hit game franchises like Final Fantasy, Dragon Quest and Kingdom Hearts. The company originated as 2 entities, Enix and Square before the merger in 2003. Aside from these franchises, the development titan is also now known for Tomb Raider, Hitman, and Deus Ex, after acquiring the UK-based publisher, Eidos Interactive. Despite their portfolio though, video game fans are divided with their move towards web3. This sentiment is largely common with other major gaming brands that are diving into blockchain technology.
SYMBIOGENESIS is slated to come out in Spring of 2023. The game will be mostly browser-based although there is a hint of possibility of an app for other platforms.